A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
This is a phase II study. All patients are stage IV non-squamas non-small cell lung cancer(NSCLC) with malignant pleura effusion, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC with malignant pleura effusion.
Lung Cancer, Non-Small Cell
DRUG: AK112
ORR of MPE, ORR of malignant pleura effusions is the proportion of subjects with CR or PR , based on WHO Evaluation Criteria ., Up to approximately 2 years
PFS of MPE, PFS of MPE is defined as the time from the date of randomization till the first documentation of effusion progression (per WHO criteria) assessed by the investigator or death due to any cause (whichever occurs first)., Up to approximately 2 years|ORR, ORR is the proportion of subjects with CR or PR , based on RECIST v1.1., Up to approximately 2 years|PFS, PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first)., Up to approximately 2 years|OS rate of 1y, Overall survival rate of 1 year，OS is the time from the date of randomization or first dosing date to death due to any cause., 1 year|DOR, DOR is the time between the first observed tumor responseto disease progression or relapse based on RECIST Version 1.1, Up to approximately 2 years|DCR, DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1, Up to approximately 2 years|OS, OS is the time from the date of randomization or first dosing date to death due to any cause., Up to approximately 2 years
This is a phase II study. All patients are stage IV non-squamas non-small cell lung cancer(NSCLC) with malignant pleura effusion, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC with malignant pleura effusion.